Last reviewed · How we verify
NCT05573035
A Study to Investigate LYL845 in Adults With Solid Tumors
Phase 1 trial testing LYL845 in Melanoma in 39 participants. Terminated before completion.
9 January 2025
Quick facts
| Lead sponsor | Lyell Immunopharma, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 19 December 2022 |
| Primary completion | 9 January 2025 |
| Estimated completion | 9 January 2025 |
| Sites | 18 locations across United States |
Drugs / interventions tested
- LYL845 — full drug profile →
Conditions studied
- Melanoma — all drugs for Melanoma →
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Lyell Immunopharma, Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Melanoma or Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent clinical researches and technological development in TIL therapy.
Matsueda S, Chen L, Li H, Yao H, et al · · 2024 · cited 23× · PMID 39264449 · DOI 10.1007/s00262-024-03793-4 -
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.
Nikolouzakis TK, Chrysos E, Docea AO, Fragkiadaki P, et al · · 2024 · cited 20× · PMID 38893120 · DOI 10.3390/cancers16111995 -
Recent advances and remaining challenges in lung cancer therapy.
Barr T, Ma S, Li Z, Yu J. · · 2024 · cited 20× · PMID 38321811 · DOI 10.1097/cm9.0000000000002991 -
Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy.
Katiyar V, Chesney J, Kloecker G. · · 2023 · cited 19× · PMID 37509394 · DOI 10.3390/cancers15143733 -
Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer.
Otegui N, Houry M, Arozarena I, Serrano D, et al · · 2023 · cited 17× · PMID 37370686 · DOI 10.3390/cancers15123076 -
TIL Therapy in Lung Cancer: Current Progress and Perspectives.
Hu W, Bian Y, Ji H. · · 2024 · cited 11× · PMID 39422665 · DOI 10.1002/advs.202409356 -
Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer.
Plaugher DR, Childress AR, Gosser CM, Esoe DP, et al · · 2024 · cited 11× · PMID 39369769 · DOI 10.1016/j.canlet.2024.217281 -
Tumor-Infiltrating Lymphocyte Therapy for Melanoma and Other Solid Tumors: Looking Back, Yet Moving Forward.
Shoushtari AN, Powell DJ. · · 2025 · cited 6× · PMID 40089327 · DOI 10.1016/j.jtct.2024.11.017
Verify or expand the search:
- PubMed search for NCT05573035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
- NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting
Other Lyell Immunopharma, Inc. trials
Trials by the same sponsor.
- NCT06153095 — A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) · Phase 1, PHASE2 · withdrawn
- NCT05891197 — A Biomarker Screening Protocol for Participants With Solid Tumors · terminated
- NCT05826535 — Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT05274451 — A Study to Investigate LYL797 in Adults With Solid Tumors · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05573035 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lyell Immunopharma, Inc.
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05573035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing